Tenaya Therapeutics (NASDAQ:TNYA) Upgraded at Lifesci Capital

Lifesci Capital upgraded shares of Tenaya Therapeutics (NASDAQ:TNYA) to a strong-buy rating in a report published on Thursday,Zacks.com reports.

A number of other analysts have also recently weighed in on TNYA. Weiss Ratings restated a “sell (d-)” rating on shares of Tenaya Therapeutics in a research note on Wednesday, January 21st. Morgan Stanley set a $2.00 target price on shares of Tenaya Therapeutics in a research note on Thursday, January 8th. Canaccord Genuity Group dropped their target price on shares of Tenaya Therapeutics from $6.00 to $5.00 and set a “buy” rating on the stock in a report on Thursday, December 18th. Chardan Capital cut their target price on shares of Tenaya Therapeutics from $9.00 to $8.00 and set a “buy” rating for the company in a research report on Friday, December 12th. Finally, HC Wainwright decreased their price target on shares of Tenaya Therapeutics from $5.00 to $3.00 and set a “buy” rating for the company in a report on Friday, December 12th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $4.50.

Tenaya Therapeutics Price Performance

NASDAQ TNYA opened at $0.89 on Thursday. The company’s 50 day simple moving average is $0.72 and its 200 day simple moving average is $1.13. Tenaya Therapeutics has a 12 month low of $0.36 and a 12 month high of $2.35. The firm has a market capitalization of $145.40 million, a PE ratio of -1.14 and a beta of 3.22.

Insider Buying and Selling at Tenaya Therapeutics

In other news, major shareholder Group Gp Lp Column III sold 3,511,826 shares of the firm’s stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $0.56, for a total value of $1,966,622.56. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders sold 8,594,047 shares of company stock valued at $5,430,207 over the last three months. 48.65% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Tenaya Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Woodline Partners LP boosted its holdings in Tenaya Therapeutics by 30,563.2% in the 1st quarter. Woodline Partners LP now owns 5,916,167 shares of the company’s stock valued at $3,373,000 after purchasing an additional 5,896,873 shares during the period. Empery Asset Management LP bought a new position in shares of Tenaya Therapeutics during the 4th quarter worth about $3,852,000. Vanguard Group Inc. increased its holdings in shares of Tenaya Therapeutics by 6.5% during the 3rd quarter. Vanguard Group Inc. now owns 5,064,857 shares of the company’s stock worth $8,205,000 after purchasing an additional 309,530 shares during the period. Millennium Management LLC raised its position in shares of Tenaya Therapeutics by 2.5% during the fourth quarter. Millennium Management LLC now owns 4,615,746 shares of the company’s stock valued at $3,284,000 after buying an additional 111,154 shares during the last quarter. Finally, Anson Funds Management LP acquired a new position in shares of Tenaya Therapeutics during the fourth quarter valued at about $2,955,000. Institutional investors own 90.54% of the company’s stock.

About Tenaya Therapeutics

Tenaya Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of gene therapy solutions for cardiovascular diseases. Leveraging a proprietary adeno‐associated virus (AAV) platform, the company aims to deliver durable, one‐time treatments for patients suffering from genetic cardiomyopathies and other inherited heart disorders. Its research programs center on optimizing vector design, delivery methods and manufacturing processes to enhance tissue specificity and minimize immune responses.

Founded in 2018 and headquartered in San Carlos, California, Tenaya has built a diversified pipeline of product candidates targeting conditions such as hypertrophic cardiomyopathy and other genetically driven forms of heart disease.